Deciphering calcineurin inhibitor nephrotoxicity: A pharmacological approach

Pharmacogenomics

Volumn 11, Issue 10, 2010, Pages 1491-1501

  Pallet, Nicolas ^a   Legendre, Christophe ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

calcineurin inhibitors; ciclosporin; interstitial fibrosis; nephrotoxicity; pharmacogenetics; renal failure; renal transplantation; tacrolimus; toxicogenomics; tubular atrophy

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; CYTOCHROME P450 3A; CYTOCHROME P450 3A5; ENDOTHELIN 1; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PROSTAGLANDIN; RAPAMYCIN; TACROLIMUS; THROMBOXANE; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; CAUSAL ATTRIBUTION; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG MONITORING; ENDOPLASMIC RETICULUM STRESS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE FREQUENCY; GENE TARGETING; GLOMERULUS FILTRATION RATE; GRAFT RECOVERY; HUMAN; LOW DRUG DOSE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PHARMACOGENOMICS; PHENOTYPE; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SYMPATHETIC TONE;

ANIMALS; CALCINEURIN; CYCLOSPORINE; ENZYME INHIBITORS; HUMANS; KIDNEY DISEASES; PHARMACEUTICAL PREPARATIONS; TACROLIMUS;

EID: 78149337086     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.137     Document Type: Review

References (76)

1. Halloran PF: Immunosuppressive drugs for kidney transplantation. N Engl. J. Med. 351(26), 2715-2729 (2004).
2. Kapturczak MH, Meier-Kriesche HU, Kaplan B: Pharmacology of calcineurin antagonists. Transplant Proc. 36(Suppl. 2), 25S-32S (2004).
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD: Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology Transplantation 78(4), 557-565 (2004).
4. Naesens M, Kuypers D, Sarwal M: Calcineurin inhibitor nephrotoxicity Clin. J. Am. Soc. Nephrol. 4(2), 481-508 (2009).
5. Cauduro RL, Costa C, Lhulier F et al.: Endothelin-1 plasma levels and hypertension in cyclosporine-treated renal transplant patients. Clin. Transplant 19(4), 470-474 (2005).
6. Lanese DM, Conger JD: Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J. Clin. Invest. 91(5), 2144-2149 (1993).
7. Perico N, Dadan J, Remuzzi G: Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J. Am. Soc. Nephrol. 1(1), 76-83 (1990).
8. Murray BM, Paller MS, Ferris TF: Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int. 28(5), 767-774 (1985).
9. Scherrer U, Vissing SF, Morgan BJ et al.: Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N. Engl. J. Med. 323(11), 693-699 (1990).
10. Conger JD, Kim GE, Robinette JB: Effects of ANG II, ETA, and TxA2 receptor antagonists on cyclosporin A renal vasoconstriction. Am. J. Physiol. 26(3 Pt 2), F443-F449 (1994).
11. Darlametsos IE, Varonos DD: Role of prostanoids and endothelins in the prevention of cyclosporine-induced nephrotoxicity. Prostaglandins Leukot. Essent. Fatty Acids 64(4-5), 231-239 (2001).
12. Campistol JM, Inigo P, Jimenez W et al.: Losartan decreases plasma levels of TGF-b1 in transplant patients with chronic allograft nephropathy. Kidney Int. 56(2), 714-719 (1999).
13. Pichler RH, Franceschini N, Young BA et al.: Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J. Am. Soc. Nephrol. 6(4), 1186-1196 (1995).
14. Khanna A, Plummer M, Bromberek C, Bresnahan B, Hariharan S: Expression of TGF-b and fbrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int. 62(6), 2257-2263 (2002).
15. Khanna AK, Plummer MS, Hilton G, Pieper GM, Ledbetter S: Anti-transforming growth factor antibody at low but not high doses limits cyclosporine-mediated nephrotoxicity without altering rat cardiac allograft survival: potential of therapeutic applications. Circulation 110(25), 3822-3829 (2004).
16. Ozdemir BH, Ozdemir FN, Demirhan B, Haberal M: TGF-p1 expression in renal allograft rejection and cyclosporine A toxicity. Transplantation 80(12), 1681-1685 (2005).
17. Buetler TM, Cottet-Maire F, Krauskopf A, Ruegg UT: Does cyclosporin A generate free radicals? Trends Pharmacol. Sci. 21(8), 288-290 (2000).
18. Justo P, Lorz C, Sanz A, Egido J, Ortiz A: Intracellular mechanisms of cyclosporin A-induced tubular cell apoptosis. J. Am. Soc. Nephrol. 14(12), 3072-3080 (2003).
19. Anglicheau D, Legendre C, Beaune P, Thervet E: Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 8(7), 835-849 (2007).
20. Coto E, Tavira B: Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation 88(Suppl. 3), S62-S67 (2009).
21. Hauser I, Schaeffeler E, Gauer S et al.: ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J. Am. Soc. Nephrol. 16(9), 1501-1511 (2005).
22. Cattaneo D, Ruggenenti P, Baldelli S et al.: ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J. Am. Soc. Nephrol. 20(6), 1404-1415 (2009).
23. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y: CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin. Pharmacol. Ther. 82(6), 711-725 (2007).
24. Fukudo M, Yano I, Yoshimura A et al.: Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet. Genomics 18(5), 413-423 (2008).
25. Klauke B, Wirth A, Zittermann A et al.: No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation. J. Heart Lung Transplant 27(7), 741-745 (2008).
26. Copeland KR, Thliveris JA, Yatscoff RW: Toxicity of cyclosporine metabolites. Ther. Drug Monit. 12(6), 525-532 (1990).
27. Roby KA, Shaw LM: Effects of cyclosporine and its metabolites in the isolated perfused rat kidney. J. Am. Soc. Nephrol. 4(2), 168-177 (1993).
28. El-Agroudy AE, Sobh MA, Hamdy AF, Ghoneim MA: A prospective, randomized study of coadministration of ketoconazole and cyclosporine a in kidney transplant recipients: ten-year follow-up. Transplantation 77(9), 1371-1376 (2004).
29. El-Dahshan KF, Bakr MA, Donia AF, Badr Ael S, Sobh MA: Ketoconazole-tacrolimus coadministration in kidney transplant recipients: two-year results of a prospective randomized study. Am. J. Nephrol. 26(3), 293-298 (2006).
30. August P, Suthanthiran M: Transforming growth factor b and progression of renal disease. Kidney Int. (Suppl. 87), S99 (2003).
31. Rudnicki MGM: Signifcance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease. Pharmacogenomics 10(3), 463-476 (2009).
32. Fan P, Ashby V, Fuller D et al.: Access and outcomes among minority transplant patients, 1999-2008, with a focus on determinants of kidney graft survival. Am. J. Transplant 10(4), 1090-1107 (2010).
33. Koziolek M, Riess R, Geiger H, Thevenod F, Hauser I: Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int. 60(2), 156-166 (2001).
34. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268(9), 6077-6080 (1993).
35. Del Moral RG, Olmo A, Osuna A et al.: Role of P-glycoprotein in chronic cyclosporine nephrotoxicity and its relationship to intrarenal angiotensin II deposits. Transplant Proc. 30(5), 2014-2016 (1998).
36. Garcia del Moral R, O'Valle F, Andujar M et al.: Relationship between P-glycoprotein expression and cyclosporin A in kidney: an immunohistological and cell culture study. Am. J. Pathol. 146(4), 398-408 (1995).
37. Andoh T, Lindsley T, Franceschini N, Bennett W: Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 62(4), 311-316 (1996). (Pubitemid 26277334)
38. Shihab F, Bennett W, Yi H, Choi S, Andoh T: Sirolimus increases transforming growth factor-b 1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int. 65(4), 1262-1271 (2004).
39. Napoli K, Wang M, Stepkowski S, Kahan B: Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions. Ther. Drug Monit. 20(2), 123-133 (1998).
40. Podder H, Stepkowski SM, Napoli KL et al.: Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J. Am. Soc. Nephrol. 12(5), 1059-1071 (2001).
41. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N Engl. J. Med. 349(24), 2326-2333 (2003).
42. di Paolo S, Teutonico A, Stallone G et al.: Cyclosporin exposure correlates with 1 year graft function and histological damage in renal transplanted patients. Nephrol. Dial. Transplant 19, 2107-2112 (2004).
43. Ekberg H, Grinyo J, Nashan B et al.: Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am. J. Transplant 7(5), 560-570 (2007).
44. Nakamura T, Nozu K, Iijima K et al.: Association of cumulative cyclosporine dose with its irreversible nephrotoxicity in Japanese patients with pediatric-onset autoimmune diseases. Biol. Pharm. Bull. 30(10), 2371-2375 (2007).
45. Seron D, Moreso F, Fulladosa X, Hueso M, Carrera M, Grinyo J: Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney Int. 61, 727-733 (2002). (Pubitemid 34102616)
46. Soin A, Rasmussen A, Jamieson NV et al.: CsA levels in the early posttransplant period-predictive of chronic rejection in liver transplantation? Transplantation 59(17), 1119-1123 (1995).
47. van Gelder T, Balk A, Zietse R, Hesse C, Mochtar BWW: Renal insuffciency after heart transplantation: a case-control study. Nephrol. Dial. Transplant 13(12), 2322-2326 (1998).
48. Roos-van Groningen MC, Scholten EM, Lelieveld PM et al.: Molecular comparison of calcineurin inhibitor-induced fbrogenic responses in protocol renal transplant biopsies. J. Am. Soc. Nephrol. 17(3), 881-888 (2006).
49. Gooch JL, Toro JJ, Guler RL, Barnes JL: Calcineurin A-a but not A-b is required for normal kidney development and function. Am. J. Pathol. 165(5), 1755-1765 (2004).
50. Gooch JL, Roberts BR, Cobbs SL, Tumlin JA: Loss of the a-isoform of calcineurin is suffcient to induce nephrotoxicity and altered expression of transforming growth factor-b. Transplantation 83(4), 439-447 (2007).
51. Kung L, Batiuk T, Palomo-Pinon S, Noujaim J, Helms L, Halloran P: Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. Am. J. Transplant 1(4), 325-333 (2001).
52. Press R, de Fijter J, Guchelaar H: Individualizing calcineurin inhibitor therapy in renal transplantation-current limitations and perspectives. Curr. Pharm. Des. 16(2), 176-186 (2010).
53. Hong F, Lee J, Piao YJ et al.: Transgenic mice overexpressing cyclophilin A are resistant to cyclosporin A-induced nephrotoxicity via peptidyl-prolyl cis-trans isomerase activity. Biochem. Biophys. Res. Commun. 316(4), 1073-1080 (2004).
54. Schiene C, Fischer G: Enzymes that catalyse the restructuring of proteins. Curr. Opin. Struct. Biol. 10(1), 40-45 (2000).
55. Shaw PE: Peptidyl-prolyl cis/trans isomerases and transcription: is there a twist in the tail? EMBO Rep. 8(1), 40-45 (2007).
56. Pallet N, Bouvier N, Bendjallabah A et al.: Cyclosporine-induced endoplasmic reticulum stress triggers phenotypic changes and death. Am. J. Transplant. 8(11), 2283-2296 (2008).
57. Dumont FJ, Staruch MJ, Koprak SL et al.: The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J. Exp. Med. 176(3), 751-760 (1992).
58. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG: Evidence that fbroblasts derive from epithelium during tissue fbrosis. J. Clin. Invest. 110(3), 341-350 (2002).
59. Liu Y: Epithelial to mesenchymal transition in renal fbrogenesis: pathologic signifcance, molecular mechanism, and therapeutic intervention. J. Am. Soc. Nephrol. 15(1), 1-12 (2004).
60. Neilson EG: Plasticity, nuclear diapause, and a requiem for the terminal differentiation of epithelia. J. Am. Soc. Nephrol. 18(7), 1995-1998 (2007).
61. Venkov CD, Link AJ, Jennings JL et al.: A proximal activator of transcription in epithelial-mesenchymal transition. J. Clin. Invest. 117(2), 482-491 (2007).
62. Slattery C, Campbell E, McMorrow T, Ryan MP: Cyclosporine A-induced renal fbrosis: a role for epithelial-mesenchymal transition. Am. J. Pathol. 167(2), 395-407 (2005).
63. Ron D: Translational control in the endoplasmic reticulum stress response. J. Clin. Invest. 110(10), 1383-1388 (2002). (Pubitemid 35396906)
64. Ron D, Walter P: Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8(7), 519-529 (2007).
65. Xu C, Bailly-Maitre B, Reed JC: Endoplasmic reticulum stress: cell life and death decisions. J. Clin. Invest. 115(10), 2656-2664 (2005).
66. Pallet N, Fougeray S, Beaune P, Legendre C, Thervet E, Anglicheau D: Endoplasmic reticulum stress: an unrecognized actor in solid organ transplantation. Transplantation 88(5), 605-613 (2009).
67. Han SW, Li C, Ahn KO et al.: Prolonged endoplasmic reticulum stress induces apoptotic cell death in an experimental model of chronic cyclosporine nephropathy. Am. J. Nephrol. 28(5), 707-714 (2008).
68. Bierut LJ, Madden PA, Breslau N et al.: Novel genes identifed in a high-density genome wide association study for nicotine dependence. Hum. Mol. Genet. 16, 24-35 (2007).
69. Berrettini W, Yuan X, Tozzi F et al.: a-5/a-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol. Psychiatry 13, 368-373 (2008).
70. Thorgeirsson TE, Geller F, Sulem P et al.: A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452, 638-642 (2008).
71. Thorgeirsson TE, Gudbjartsson DF, Surakka I et al.: Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat. Genet. 42, 448-453 (2010).
72. Amos CI, Wu X, Broderick P, Gorlov IP et al.: Genome-wide association scan of tag SNPs identifes a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 40, 616-622 (2008).
73. Hung RJ, McKay JD, Gaborieau V et al.: A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452, 633-637 (2008).
74. Caporaso N, Gu F, Chatterjee N et al.: Genome-wide and candidate gene association study of cigarette smoking behaviors. PLoS One 4, e4653 (2009).
75. Liu JZ, Tozzi F, Waterworth DM et al.: Meta-ana lysis and imputation refnes the association of 15q25 with smoking quantity. Nat. Genet. 42, 436-440 (2010).
76. Saccone SF, Hinrichs AL, Saccone NL et al.: Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum. Mol. Genet. 16, 36-49 (2007)